ORIGINAL PAPER

Regioselective synthesis and antibacterial activity of 3-(cyanoacetyl)indole-based kojic acid derivatives

Robabeh Baharfar · Sakineh Asghari · Maryam Kiani

Received: 6 May 2014/Accepted: 7 September 2014/Published online: 24 September 2014 © Springer-Verlag Wien 2014

Abstract A simple and facile protocol for the regioselective synthesis of diastereomeric 3-substituted indole derivatives is described by the three-component condensation of 3-(cyanoacetyl)indole, aldehydes, and kojic acid in the presence of ammonium acetate as catalyst. The synthesized compounds were tested for their antibacterial effects against *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Bacillus subtilis*. One compound showed good activity against *B. subtilis* compared with the standard drugs gentamicin and chloramphenicol.

Keywords Three-component reaction · 3-(Cyanoacetyl)indole · Kojic acid · Ammonium acetate · Antibacterial activities

Introduction

Multi-component reactions (MCRs) are of increasing importance in organic and medicinal chemistry [1, 2]. MCRs are reactions in which three or more reagents react in a one-pot procedure to give a single product [3]. These reactions have become increasingly popular during the last decade [4–6]. MCRs offer a wide range of advantages over single-component reactions such as high degree of atom economy, convergence, ease of execution, and a quick access to complex molecules [7].

Indole fragment is featured widely in broad ranges of pharmacologically and biologically active compounds [8–13]. Therefore, the synthesis and selective functionalization

e-mail: Baharfar@umz.ac.ir

of indoles have been the focus of active research over the years [14–17]. In particular, 3-substituted indoles are privileged scaffolds in medicinal chemistry, which have been found in a fascinating array of bioactive natural products and pharmaceutical compounds [18–25]. These scaffolds are found in a number of biologically active compounds, especially with anti-cancer [26–29], anti-tumor [30], hypoglycemic [31], anti-inflammatory [32], analgesic [33, 34], and anti-pyretic activities [35].

Kojic acid is a natural product that has been isolated from various strains of microorganisms such as *Penicillium*, *Aspergillus*, and *Gluconacetobacter* [36]. Kojic acid and its derivatives have shown to possess various bioactivities such as anti-microbial [37, 38], cosmetic skin-whitening [39], anti-speck [40], pesticide and insecticide [41], anti-tumor [42], anti-diabetic [43], and anti-proliferative activities [44].

Therefore, in continuation of our previous work on the synthesis of novel biologically active heterocyclic compounds [45–47], we wish to report herein a simple protocol for the synthesis of novel 3-substituted indole and kojic acid derivatives **4a–4j** by the three-component condensation of 3-(cyanoacetyl)indole (1), benzaldehyde derivatives **2**, and kojic acid (**3a**) in the presence of ammonium acetate as catalyst (Scheme 1).

Also, antibacterial activities of 3-substituted indole derivatives **4a–4j** were investigated against *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Bacillus subtilis*.

Results and discussion

Chemistry

In order to optimize the reaction conditions, the threecomponent reaction of 3-(cyanoacetyl)indole (1) with

R. Baharfar (🖂) · S. Asghari · M. Kiani

Department of Chemistry, University of Mazandaran, P. O. Box 47415, Babolsar, Iran



4-Cl, 2-Br, 3-Cl, 4-CN, 4-Br, 4-NO₂, 4-NMe₂, 2-OMe

Table 1 Optimization of catalysts

Entry	Catalyst (mol%)	Time/h	Yield/%
1	No catalyst	24	NR ^a
2	Piperidine (30)	18	NR
3	DABCO (30)	18	40
4	CH_3COONH_4 (10)	18	20
5	CH ₃ COONH ₄ (20)	18	55
6	CH_3COONH_4 (30)	18	95
7	CH_3COONH_4 (40)	18	95

^a No reaction

benzaldehyde (**2a**) and kojic acid (**3a**) was investigated as model reaction. Initially, the reaction was carried out without any catalysts, but did not give any product (Table 1, entry 1). Also, when piperidine was used as the catalyst, the reaction did not proceed (Table 1, entry 2). The best result was obtained when the reaction was performed in the presence of ammonium acetate as catalyst. We also evaluated the amount of catalyst required for this transformation. It was found that when the amount of ammonium acetate increased from 10 to 20 mol% and 30 mol%, the yields increase from 20 to 55 % and 95 %, respectively. Using 30 mol% of ammonium acetate is sufficient to promote the reaction. Additional amounts of the catalyst did not improve the product yields (Table 1, entry 7).

To select the optimal solvent and temperature for this reaction, we performed the model reaction in different solvents, and at room temperature and at reflux conditions. It was observed that when using EtOH as the solvent at reflux condition, shorter reaction time and higher yield resulted (Table 2).

To study the scope the reaction, a series of substituted aldehydes 2a-2l and kojic acid (3a) or some example of other compounds containing an enol group 3b-3d were

 Table 2
 Optimization of solvent and temperature

Entry	Solvent	T/°C	Time/h	Yield/%
1	THF	r.t	24	NR
2	THF	Reflux	24	NR
3	1,4-Dioxane	r.t	24	NR
4	1,4-Dioxane	Reflux	24	NR
5	H ₂ O	r.t	24	NR
6	H ₂ O	Reflux	24	NR
7	MeOH	r.t	24	Trace
8	MeOH	Reflux	24	55
9	EtOH	r.t	24	Trace
10	EtOH	Reflux	18	95

reacted with 3-(cyanoacetyl)indole (1) using ammonium acetate (30 mol% in boiling EtOH. Under the optimized reaction conditions, a series of 3-(cyanoacetyl)indole derivatives 4a-4j were synthesized in excellent yields (Table 3). As presented in Table 3, the reaction of aldehydes with electron accepting groups leads to the highest yields and the shortest reaction times (entries 7 and 10), whereas the reaction of aldehydes 2k, 2l with strong electron releasing group (e.g., NMe₂) and the other OH acids 3b-3d (entries 13–15) did not proceed, therefore no products could be isolated. The expected structures of the products 4m-4o are depicted in Fig. 1.

As shown in Fig. 2, compounds **4a–4j** possess two chiral centers and therefore, they can exist as two diastereomeric pairs. For example, compound **4a** exists as two diastereomeric pairs, RR or its enantiomer SS, and RS or its enantiomer SR.

The ¹H NMR spectrum of **4a** shows existence of both two diastereomeric pairs. Unfortunately, all our attempts to separate the two diastereomeric pairs including recrystallization, flash and column chromatography by using

Table 3 Synthesis of three-substituted indole derivatives 4a-4j

Entry	Product	Aldehyde	OH acid	Time/h	M.p./°C	Yield/%	I/% ^a	∏/% ^b
1	4 a	PhCHO (2a)	3a	18	236–238	95	56	39
2	4 b	4-MeO-PhCHO (2b)	3a	28	232-234	91	53	38
3	4 c	3-MeO-PhCHO (2c)	3a	24	211-213	80	47	33
4	4d	4-Me-PhCHO (2d)	3a	26	233-235	92	55	37
5	4 e	4-Cl-PhCHO (2e)	3a	14	217-219	92	55	37
6	4f	3-Cl-PhCHO (2f)	3a	11	210-212	91	58	33
7	4g	4-CN-PhCHO (2g)	3a	8	235-237	97	60	37
8	4h	4-Br-PhCHO (2h)	3a	16	223-225	93	56	37
9	4 i	2-Br-PhCHO (2i)	3a	13	219-221	90	58	32
10	4j	4-NO ₂ -PhCHO (2j)	3a	7	263-265	97	57	40
11	4k	4-Me ₂ N-PhCHO (2k)	3a	48	-	Trace	-	_
12	41	2-MeO-PhCHO (21)	3a	48	-	Trace	-	_
13	4m	2a	2,5-Dihydroxycyclohexa- 2,5-diene-1,4-dione (3b)	48	_	NR	-	-
14	4n	2a	Phenol (3c)	48	-	Trace	_	_
15	40	2a	4-Nitrophenol (3d)	48	_	Trace	-	-

^{a, b} Determined by ¹H NMR spectroscopy

different ratios of various solvents have failed and we could only isolate the mixture of two diastereomers.

The structures and the purities of the products 4a-4j were determined on the basis of their elemental analyses, mass spectra, ¹H and ¹³C NMR and IR spectroscopic data. The ¹H NMR spectrum of **4a** in DMSO- d_6 for the first diastereomeric pair (RR/SS or RS/SR) exhibited two doublet of doublets at 4.07 and 4.25 ppm (${}^{2}J_{\text{HH}} = 16.0$ and ${}^{3}J_{\rm HH} = 6.0$ Hz) for CH₂ group (AB system), two doublets at 5.00 ppm for H_b and 5.74 ppm for H_a (${}^{3}J_{HH} = 11.6$ Hz), a triplet at 5.64 ppm (${}^{3}J_{HH} = 6.4$ Hz) for OH group and a singlet at 6.10 ppm for vinyl proton of kojic acid ring. The other signals at 7.16-7.50, 7.61, and 8.11 ppm consisted of characteristic resonances in the appropriate regions for nine aromatic protons along with three singlets at 8.91, 9.28, and 12.43 ppm for vinyl proton of indole, OH and NH groups, respectively. The proton decoupled ¹³C NMR spectrum of 4a showed 22 signals, which is in agreement with the proposed structure.

The ¹H NMR spectrum of **4a** in DMSO- d_6 for the second diastereomeric pair (RR/SS or RS/SR) exhibited two doublet of doublets at 4.44 and 4.48 ppm (² $J_{HH} = 16.0$ and ³ $J_{HH} = 6.4$ Hz) for CH₂ group (AB system), two doublets at 5.18 ppm (³ $J_{HH} = 10.8$ Hz) and 5.61 ppm (³ $J_{HH} = 11.2$ Hz) for H_b and H_a, a triplet at 5.79 ppm (³ $J_{HH} = 6.4$ Hz) for OH group and a singlet at 6.36 ppm for vinyl proton of kojic acid ring. The other signals at 7.16–7.50, 7.52, and 8.05 consisted of characteristic resonances in the appropriate regions for aromatic protons along with three singlets at 8.75, 9.43, and 12.38 ppm for vinyl proton of indole, OH and NH groups, respectively. The proton decoupled ¹³C NMR spectrum of **4a**

showed 22 signals, which is in agreement with the proposed structure. The ¹H and ¹³C NMR spectra of **4b–4j** were similar to those of **4a**, except to the substituted phenyl moiety that exhibited characteristic resonances in the appropriate regions of the spectra.

A plausible mechanism for the formation of products 4a-4j is given in Scheme 2. The formation of these products can be rationalized by initial formation of intermediate 5 by Knoevenagel condensation of the aldehyde 2 and 3-(cyanoacetyl)indole. As shown in Scheme 2, the anion of kojic acid can attack to intermediate 5 in four routes: Michael-type addition (route a), direct addition (route b), C-alkylation (route c), or O-alkylation (route d). Among these four routes, the reaction proceeded regioselectively via route a, and led to intermediate 7. Then, enolization and protonation of 7 in the reaction conditions result in final product 4.

Antibacterial activity

The synthesized compounds were evaluated for their antibacterial activity against two Gram-positive *S. aureus* and *B. subtilis* and two Gram-negative bacterial strains *E. coli* and *P. aeruginosa*. Standard antibacterial drug gentamicin and chloramphenicol were also tested under similar conditions against these organisms (Table 4). Compound **4e** (*p*-chlorobenzaldehyde derivative) demonstrated excellent activity against *S. aureus* and *B. subtilis*, even more than standard compounds. Except compound **4f** (*m*-chlorobenzaldehyde derivative), none of the compounds did show antibacterial activities against *P. aeruginosa*. Also, compounds **4e**, **4f**, **4h**,



Fig. 1 The expected structures of the products 4m-4o

4i, and **4j** (with Cl, Br, or NO₂ substituent) exhibited good activity against *E. coli*.

Experimental

All chemicals and reagents were purchased from Fluka and Merck and used without further purification. Melting points were measured on an Electrothermal 9100 apparatus. NMR spectra were recorded on a Bruker DRX-400 AVANCE instrument (400.1 MHz for ¹H, 100.6 MHz for ¹³C) with DMSO- d_6 as solvent. Chemical shifts (δ) are given in parts per million (ppm) relative to TMS, and coupling constants (*J*) are reported in hertz (Hz). IR spectra were recorded on an FT-IR Bruker vector 22 spectrometer. Mass spectra were recorded on a Finnigan-Matt 8430 mass spectrometer operating at an ionization potential of 70 eV. Elemental analyses were carried on a Perkin-Elmer 2400II CHNS/O Elemental Analyzer. 3-(Cyanoacetyl)indole was prepared as reported in the literature [48].

General procedure for the synthesis of compounds 4a-4j

A mixture of 3-(cyanoacetyl)indole (1 mmol), benzaldehyde derivatives (1 mmol), kojic acid (1 mmol), and ammonium acetate (30 mol%) in 5 cm³ ethanol was refluxed for appropriate time as indicated in Table 2. The completion of the reaction was indicated by the disappearance of the starting material in thin layer chromatography (EtOAc/*n*-hexane 18:2). After completion of the reaction, the product was recrystallized from methanol and washed with water.

3-[3-Hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-3-phenylpropanenitrile (**4a**, C₂₄H₁₈N₂O₅)

White powder, 0.39 g (95 %); m.p.: 236-238 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).



Fig. 2 Structures of two diastereomeric pairs of 4a (I (RR/SS or RS/SR) and II (RR/SS or RS/SR))

4a-I (RR/SS or RS/SR): yield 56 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.07$ and 4.25 (2dd, AB system, 2H, ² $J_{\rm HH} = 16.0$ Hz, ³ $J_{\rm HH} = 6.0$ Hz, CH₂), 5.00 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 5.64 (t, 1H, ³ $J_{\rm HH} = 6.4$ Hz, OH), 5.74 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 6.10 (s, 1H, CH_{kojic}), 7.16–7.50 (m, 7H, 7CH_{Ar}), 7.61 (d, 1H, ³ $J_{\rm HH} = 7.2$ Hz, CH_{Ar}), 8.11 (d, 1H, ³ $J_{\rm HH} = 7.2$ Hz, CH_{Ar}), 8.91 (s, 1H, CH–NH), 9.28 (s, 1H, OH), 12.43 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.47$, 43.35 (2CH), 59.67 (CH₂), 109.26 (CH_{kojic}), 113.05 (CH_{indole}), 114.73, 118.10 (2C_{indole}), 121.63, 123.17, 124.19 (3CH_{indole}), 125.65 (C_{indole}), 128.29, 128.58, 129.19, 136.89 (5CH, C_{Ar}), 137.29 (CH_{indole}), 137.45 (CN), 142.14, 147.42, 167.30 (3C_{kojic}), 173.68, 182.66 (2CO) ppm.

4a-II (RR/SS or RS/SR): yield 39 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.44$ and 4.48 (2dd, AB system, 2H, ${}^{2}J_{\text{HH}} = 16.0$ Hz, ${}^{3}J_{\text{HH}} = 6.4$ Hz, CH₂), 5.18 (d, 1H, ${}^{3}J_{\text{HH}} = 10.8 \text{ Hz}$, CH), 5.61 (d, 1H, ${}^{3}J_{\text{HH}} = 11.2$ Hz, CH), 5.79 (t, 1H, ${}^{3}J_{\text{HH}} = 6.4$ Hz, OH), 6.36 (s, 1H, CH_{koiic}), 7.16–7.50 (m, 7H, 7CH_{Ar}), 7.52 (d, 1H, ${}^{3}J_{\text{HH}} = 7.6$ Hz, CH_{Ar}), 8.05 (d, 1H, ${}^{3}J_{\text{HH}} = 7.2$ Hz, CH_{Ar}), 8.75 (s, 1H, CH-NH), 9.43 (s, 1H, OH), 12.38 (s, 1H, NH) ppm; 13 C NMR (100.6 MHz, DMSO- d_6): $\delta = 42.04, 44.42$ (2CH), 59.91 (CH₂), 109.38 (CH_{koiic}), 113.06 (CH_{indole}), 115.30, 118.33 (2C_{indole}), 121.68, 123.18, 124.20 (3CH_{indole}), 125.73 (C_{indole}), 128.30, 128.97, 129.36, 137.20 (5CH, CAr), 137.36 (CH_{indole}), 137.66 (CN), 142.45, 148.21, 168.17 (3Ckojic), 174.00, 183.55 (2CO) ppm; IR (KBr): $\overline{v} = 3,425$ (OH), 3,247 (NH), 2,250 (CN), 1,630 (C=O), 1,599 (C=C), 1,097 (C-O) cm⁻¹; MS (70 eV): m/z (%) = 414 (M^{+,}, 8), 270 (M⁺-



3-[3-Hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-3-(4-methoxyphenyl)propanenitrile (**4b**, C₂₅H₂₀N₂O₆)

White powder, 0.40 g (91 %); m.p.: 232–234 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4b-I (RR/SS or RS/SR): yield 53 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 3.77$ (s, 3H, CH₃), 4.04–4.26 (m, 2H, CH₂), 4.94 (d, 1H, ³ $J_{\text{HH}} = 10.8$ Hz, CH), 5.55 (d, 1H, ³ $J_{\text{HH}} = 10.8$ Hz, CH), 5.67–5.71 (m, 1H, OH), 6.09 (s, 1H, CH_{kojic}), 6.99 (d, 1H, ³ $J_{\text{HH}} = 8.8$ Hz, CH_{Ar}), 7.19–7.53 (m, 6H, 6CH_{Ar}), 8.09 (d, 1H, ³ $J_{\text{HH}} = 7.6$ Hz, CH_{Ar}), 8.89 (s, 1H, CH–NH), 9.29 (s, 1H, OH), 12.42 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.54$, 42.66 (2CH), 55.42 (OCH₃), 59.69 (CH₂), 109.23 (CH_{kojic}), 113.04 (CH_{indole}), 114.53, 115.41 (2C_{indole}), 121.69, 123.17, 124.22 (3CH_{indole}), 125.66 (C_{indole}), 128.68, 129.59, 129.75, 130.11 (4CH, 2C_{Ar}), 137.19 (CH_{indole}), 141.90 (CN), 148.57, 159.12, 167.20 (3C_{koiic}), 173.70, 182.78 (2CO) ppm.

4b-II (RR/SS or RS/SR): yield 38 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 3.62$ (s, 3H, CH₃), 4.39-4.50 (m, 2H, CH₂), 5.12 (d, 1H, ³ $J_{\rm HH} = 11.2$ Hz, CH), 5.70 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 5.82 (t, 1H, ³ $J_{\rm HH} = 6.8$ Hz, OH), 6.35 (s, 1H, CH_{kojic}), 6.79 (d, 1H, ³ $J_{\rm HH} = 8.8$ Hz, CH_{Ar}), 7.19–7.53 (m, 6H, 6CH_{Ar}), 8.06 (d, 1H, ³ $J_{\rm HH} = 7.2$ Hz, CH_{Ar}), 8.74 (s, 1H, CH–NH), 9.30 (s, 1H, OH), 12.41 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 42.30$, 43.66 (2CH), 55.59 (OCH₃), 59.92 (CH₂), 109.34 (CH_{koiic}), 113.05 (CH_{indole}), 114.68, 118.14

Table 4 Antibacterial activity of the complex using Kirby–Bauer technique (zone of growth inhibition/mm)

Product	E. coli	P. aeruginosa	S. aureus	B. subtilis
4a	NE ^a	NE	15.0 ± 1.4	14.5 ± 1.4
4b	NE	NE	12.0 ± 1.4	14.0 ± 1.4
4c	NE	NE	13.0 ± 1.4	14.5 ± 1.4
4d	NE	NE	14.0 ± 1.4	12.5 ± 0.7
4e	11.5 ± 0.7	NE	22.0 ± 1.4	19.5 ± 0.7
4f	14.0 ± 1.4	9.5 ± 0.7	11.5 ± 0.7	14.0 ± 1.4
4g	NE	NE	11.0 ± 1.4	9.5 ± 0.7
4h	11.5 ± 0.7	NE	14.5 ± 0.7	17.0 ± 1.4
4i	13.0 ± 1.4	NE	14.0 ± 1.4	13.0 ± 0.7
4j	10.0 ± 1.4	NE	9.5 ± 0.7	12.5 ± 0.7
Gentamicin (10 µg/disc)	19.6 ± 1.1	15.6 ± 0.5	20.3 ± 1.5	26.0 ± 1.7
Chloramphenicol (30 µg/disc)	20.7 ± 1.5	NE	21.7 ± 0.6	22.3 ± 1.2

Concentration of compound: 20 mg cm^{-3}

Mueller-Hinton agar plate

^a No effect

(2C_{indole}), 121.70, 123.18, 124.23 (3CH_{indole}), 125.67 (C_{indole}), 128.69, 129.60, 129.76, 130.12 (4CH, 2C_{Ar}), 137.31 (CH_{indole}), 142.18 (CN), 148.58, 159.44, 168.08 (3C_{kojic}), 174.02, 182.79 (2CO) ppm; IR (KBr): $\bar{\nu} = 3,427$ (OH), 3,233 (NH), 2,259 (CN), 1,632 (C=O), 1,515 (C=C), 1,033 (C–O) cm⁻¹; MS (70 eV): m/z (%) = 444 (M⁺, 5), 300 (M⁺-C₉H₆NO, 27), 261 (M⁺-C₁₁H₇N₂O, 25), 144 (M⁺-C₁₆H₁₄NO₅, 100), 116 (M⁺-C₁₇H₁₄NO₆, 20). 3-[3-Hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-3-(3-methoxyphenyl)propanenitrile (**4c**, C₂₅H₂₀N₂O₆)

White powder, 0.35 g (80 %); m.p.: 211–213 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4c-I (RR/SS or RS/SR): yield 47 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 3.81$ (s, 3H, CH₃), 4.08 and 4.24 (2dd, 2H, ² $J_{\rm HH} = 16.0$ Hz, ³ $J_{\rm HH} = 5.6$ Hz, CH₂), 4.98 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 5.64 (br s, 1H, OH), 5.74 (d, 1H, ³ $J_{\rm HH} = 12.0$ Hz, CH), 6.10 (s, 1H, CH_{kojic}), 6.73–7.29 (m, 6H, 6CH_{Ar}), 7.51 (t, 1H, ³ $J_{\rm HH} = 8.4$ Hz, CH_{Ar}), 8.11 (d, 1H, ³ $J_{\rm HH} = 8.0$ Hz, CH_{Ar}), 8.92 (s, 1H, CH–NH), 9.28 (s, 1H, OH), 12.43 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.35$, 43.28 (2CH), 55.46 (CH₃), 59.71 (CH₂), 109.30 (CH_{kojic}), 113.06 (CH_{indole}), 113.45, 114.31 (2C_{indole}), 114.93, 118.07, 120.94 (3CH_{indole}), 121.64 (C_{indole}), 123.19, 124.20, 125.66, 130.26, 137.25, 137.36 (4CH, 2C_{Ar}), 138.23 (CH_{indole}), 139.00 (CN), 147.28, 159.69, 167.24 (3C_{kojic}), 173.68, 182.66 (2CO) ppm.

4c-II (RR/SS or RS/SR): yield 33 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 3.66$ (s, 3H, CH₃), 4.40–4.51 (m, 2H, CH₂), 5.16 (d, 1H, ${}^{3}J_{HH} = 11.2$ Hz, CH), 5.61 (d, 1H, ${}^{3}J_{HH} = 11.2$ Hz, CH), 5.79 (t, 1H, ${}^{3}J_{\rm HH} = 6.4$ Hz, OH), 6.37 (s, 1H, CH_{koiic}), 6.73–7.29 (m, 6H, 6CH_{Ar}), 7.36 (t, 1H, ${}^{3}J_{HH} = 7.6$ Hz, CH_{Ar}), 8.07 (d, 1H, ${}^{3}J_{\text{HH}} = 8.0$ Hz, CH_{Ar}), 8.77 (s, 1H, CH–NH), 9.46 (s, 1H, OH), 12.40 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.93$, 44.33 (2CH), 55.60 (CH₃), 59.94 (CH₂), 109.43 (CH_{kojic}), 113.07 (CH_{indole}), 113.54, 114.73 (2C_{indole}), 115.33, 118.34, 121.26 (3CH_{indole}), 121.68 (C_{indole}), 123.20, 124.24, 125.72, 130.43, 137.29, 137.48 (4CH, 2CAr), 138.24 (CHindole), 139.01 (CN), 148.11, 159.95, 168.09 (3Ckojic), 174.01, 183.53 (2CO) ppm; IR (KBr): $\overline{v} = 3,421$ (OH), 3,224 (NH), 2,261 (CN), 1,633 (C=O), 1,596 (C=C), 1,042 (C-O) cm^{-1} ; MS (70 eV): m/z (%) = 444 (M⁺, 2), 262 (M⁺-C₁₁H₆N₂O, 96), 144 $(M^+-C_{16}H_{14}NO_5, 100), 116 (M^+-C_{17}H_{14}NO_6, 34).$

3-[3-Hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-3-(4-methylphenyl)propanenitrile (4d, C₂₅H₂₀N₂O₅)

White powder, 0.39 g (92 %); m.p.: 233–235 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4d-I (RR/SS or RS/SR): yield 55 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 2.32$ (s, 3H, CH₃), 4.03–4.27 (m, 2H, CH₂), 4.96 (d, 1H, ³ $J_{\text{HH}} = 11.2$ Hz, CH), 5.59 (d, 1H, ³ $J_{\text{HH}} = 11.2$ Hz, CH), 5.67 (t, 1H, ³ $J_{\text{HH}} = 6.4$ Hz, OH), 6.09 (s, 1H, CH_{kojic}), 7.04–7.53 (m, 7H, 7CH_{Ar}), 8.10 (d, 1H, ³ $J_{\text{HH}} = 7.2$ Hz, CH_{Ar}), 8.90 (s, 1H, CH–NH), 9.27 (s, 1H, OH), 12.43 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 20.97$ (CH₃), 42.03, 44.00 (2CH), 59.65 (CH₂), 109.21 (CH_{kojic}),

113.04 (CH_{indole}), 114.72, 118.13 (2C_{indole}), 121.67, 123.21, 124.27 (3CH_{indole}), 125.62 (C_{indole}), 128.44, 129.75, 133.78, 134.60 (4CH, 2C_{Ar}), 137.28 (CH_{indole}), 137.60 (CN), 141.93, 147.61, 167.27 (3C_{kojic}), 173.66, 182.66 (2CO) ppm.

4d-II (RR/SS or RS/SR): yield 37 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 2.14$ (s, 3H, CH₃), 4.41 and 4.47 (2dd, AB system, 2H, ${}^{2}J_{\rm HH} = 16.0$ Hz, ${}^{3}J_{\rm HH} = 6.0$ Hz, CH₂), 5.15 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.71 (d, 1H, ${}^{3}J_{\rm HH} = 11.6$ Hz, CH), 5.82 (t, 1H, ${}^{3}J_{\rm HH} = 6.8$ Hz, OH), 6.35 (s, 1H, CH_{kojic}), 7.04–7.53 (m, 7H, 7CH_{Ar}), 8.05 (d, 1H, ${}^{3}J_{HH} = 7.2$ Hz, CH_{Ar}), 8.77 (s, 1H, CH-NH), 9.28 (s, 1H, OH), 12.42 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 21.16$ (CH₃), 42.95, 44.07 (2CH), 59.89 (CH₂), 109.33 (CH_{kojic}), 113.05 (CH_{indole}), 115.37, 118.38 (2C_{indole}), 121.68, 123.22, 124.28 (3CH_{indole}), 125.69 (C_{indole}), 128.81, 129.91, 133.79, 134.61 (4CH, 2CAr), 137.29 (CH_{indole}), 137.90 (CN), 141.94, 148.41, 168.14 (3C_{koiic}), 174.00, 183.65 (2CO) ppm; IR (KBr): $\overline{v} = 3,425$ (OH), 3,248 (NH), 2,260 (CN), 1,632 (C=O), 1,519 (C=C), 1,036 (C-O) cm⁻¹; MS: m/z (%) = 428 (M⁺⁻, 8), 284 (M⁺-C₉H₆NO, 43), 245 (M⁺-C₁₁H₇N₂O, 19), 144 (M⁺-C₁₆H₁₄NO₄, 100), 116 (M^+ - $C_{17}H_{14}NO_5$, 48).

3-(4-Chlorophenyl)-3-[3-hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)propaneni-trile (4e, C₂₇H₁₇ ClN₂O₅)

White powder, 0.41 g (92 %); m.p.: 217–219 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4e-I (RR/SS or RS/SR): yield 55 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.05-4.28$ (m, 2H, CH₂), 5.04 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 5.77 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 5.69 (br s, 1H, OH), 6.13 (s, 1H, CH_{kojic}), 7.21-7.67 (m, 7H, 7CH_Ar), 8.11 (d, 1H, ³ $J_{\rm HH} = 7.6$ Hz, CH_Ar), 8.89 (s, 1H, CH–NH), 9.39 (s, 1H, OH), 12.45 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.42$, 42.70 (2CH), 59.66 (CH₂), 109.31 (CH_{kojic}), 113.08 (CH_{indole}), 114.69, 117.94 (2C_{indole}), 121.62, 123.23, 124.25 (3CH_{indole}), 125.61 (C_{indole}), 129.23, 130.46, 130.87, 133.08 (4CH, 2C_{Ar}), 135.81 (CH_{indole}), 137.36 (CN), 142.23, 146.92, 167.42 (3C_{kojic}), 173.70, 182.44 (2CO) ppm.

4e-II (RR/SS or RS/SR): yield 37 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.41-4.51$ (m, 2H, CH₂), 5.20 (d, 1H, ³ $J_{HH} = 10.8$ Hz, CH), 5.63 (d, 1H, ³ $J_{HH} = 10.8$ Hz, CH), 5.84 (br s, 1H, OH), 6.39 (s, 1H, CH_{kojic}), 7.21-7.67 (m, 7H, 7CH_{Ar}), 8.07 (d, 1H, ³ $J_{HH} = 7.6$ Hz, CH_{Ar}), 8.76 (s, 1H, CH–NH), 9.55 (s, 1H, OH), 12.44 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.88$, 43.76 (2CH), 59.89 (CH₂), 109.44 (CH_{kojic}), 113.09 (CH_{indole}), 115.22, 118.23 (2C_{indole}), 121.67, 123.28, 124.32 (3CH_{indole}), 125.69 (C_{indole}), 129.37, 130.47, 130.88, 133.40 (4CH, 2C_{Ar}), 136.57 (CH_{indole}), 137.43 (CN), 142.54, 147.65, 168.27 (3C_{kojic}), 174.03, 183.27 (2CO) ppm; IR (KBr): $\bar{\nu} = 3,417$ (OH), 3,239 (NH), 2,259 (CN), 1,632 (C=O), 1,594 (C=C), 1,035 (C=O) cm⁻¹; MS (70 eV): m/z (%) = 448 (M⁺, 9), 450 (M⁺+2, 3), 304 (M⁺-C₉H₆NO, 26), 306 (M⁺+2-C₉H₆NO, 14), 265 (M⁺-C₁₁H₇N₂O, 14), 267 (M⁺+2-C₁₁H₇N₂O, 6), 144 (M⁺-C₁₅H₁₁ClNO₄, 100), 116 (M⁺-C₁₆H₁₁ClNO₅, 33).

3-(3-Chlorophenyl)-3-[3-hydroxy-6-(hydroxymethyl)-4oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-

propanenitrile (**4f**, C₂₇H₁₇ ClN₂O₅)

White powder, 0.40 g (91 %); m.p.: 210–212 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4f-I (RR/SS or RS/SR): yield 58 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.07$ and 4.25 (2dd, AB system, 2H, ² $J_{\rm HH} = 16.0$ Hz, ³ $J_{\rm HH} = 6.0$ Hz, CH₂), 5.04 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 5.65 (t, 1H, ³ $J_{\rm HH} = 6.4$ Hz, OH), 5.81 (d, 1H, ³ $J_{\rm HH} = 11.6$ Hz, CH), 6.13 (s, 1H, CH_{kojic}), 7.20–7.76 (m, 7H, 7CH_{Ar}), 8.11 (d, 1H, ³ $J_{\rm HH} = 7.2$ Hz, CH_{Ar}), 8.94 (d, 1H, ³ $J_{\rm HH} = 2.8$ Hz, CH–NH), 9.42 (s, 1H, OH), 12.46 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.36$, 42.86 (2CH), 59.68 (CH₂), 109.37 (CH_{kojic}), 113.10 (CH_{indole}), 114.70, 117.90 (2C_{indole}), 121.62, 123.22, 124.24 (3CH_{indole}), 125.64 (C_{indole}), 127.45, 128.33, 128.58, 131.12, 133.72, 137.31 (4CH, 2C_{Ar}), 137.55 (CH_{indole}), 139.22 (CN), 142.36, 146.70, 167.40 (3C_{kojic}), 173.69, 182.34 (2CO) ppm.

4f-II (RR/SS or RS/SR): yield 33 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.45-4.52$ (m, 2H, CH₂), 5.20 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.67 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.80 (br s, 1H, OH), 6.39 (s, 1H, CH_{koiic}), 7.20–7.76 (m, 7H, 7CH_{Ar}), 8.07 (d, 1H, ${}^{3}J_{\text{HH}} = 7.6 \text{ Hz}, \text{ CH}_{\text{Ar}}$), 8.79 (d, 1H, ${}^{3}J_{\text{HH}} = 2.8 \text{ Hz}, \text{ CH}_{\text{--}}$ NH), 9.59 (s, 1H, OH), 12.44 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.65, 44.00$ (2CH), 59.91 (CH₂), 109.51 (CH_{koiic}), 113.11 (CH_{indole}), 115.14, 118.21 (2C_{indole}), 121.67, 123.27, 124.30 (3CH_{indole}), 125.71 (C_{indole}), 128.00, 128.45, 128.73, 131.26, 133.97, 137.37 (4CH, 2CAr), 137.56 (CH_{indole}), 139.94 (CN), 142.68, 147.42, 168.24 (3Ckojic), 174.00, 183.15 (2CO) ppm; IR (KBr): $\overline{v} = 3,481$ (OH), 3,293 (NH), 2,248 (CN), 1,633 (C=O), 1,579 (C=C), 1,088 (C-O) cm^{-1} ; MS: m/z (%) = 448 (M^{+.}, 3), 450 (M^{+.}+2, 1), 304 $(M^{+} - C_9 H_6 NO, 8), 306 (M^{+} + 2 - C_9 H_6 NO, 9), 144$ $(M^+-C_{15}H_{11}CINO_4, 100), 116 (M^+-C_{16}H_{11}CINO_5, 30).$

3-[3-Hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-3-(4-isocyanophenyl)-

propanenitrile (4g, C₂₅H₁₇ N₃O₅)

White powder, 0.42 g (97 %); m.p.: 235–237 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4g-I (RR/SS or RS/SR): yield 60 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.06$ and 4.24 (2dd, AB

system, 2H, ${}^{2}J_{\rm HH} = 16.0$ Hz, ${}^{3}J_{\rm HH} = 6.4$ Hz, CH₂), 5.11 (d, 1H, ${}^{3}J_{\rm HH} = 11.6$ Hz, CH), 5.64 (t, 1H, ${}^{3}J_{\rm HH} = 6.4$ Hz, OH), 5.82 (d, 1H, ${}^{3}J_{\rm HH} = 11.6$ Hz, CH), 6.12 (s, 1H, CH_{kojic}), 7.20–7.30 (m, 2H, 2CH_{Ar}), 7.50–7.55 (m, 1H, CH_{Ar}), 7.84 (d, 2H, ${}^{3}J_{\rm HH} = 8.4$ Hz, 2CH_{Ar}), 7.95 (d, 2H, ${}^{3}J_{\rm HH} = 8.4$ Hz, 2CH_{Ar}), 8.10 (d, 1H, ${}^{3}J_{\rm HH} = 8.0$ Hz, CH_{Ar}), 8.90 (s, 1H, CH–NH), 9.47 (s, 1H, OH), 12.45 (s, 1H, NH) ppm; 13 C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.23$, 43.08 (2CH), 59.63 (CH₂), 109.37 (CH_{kojic}), 111.29 (CH_{indole}), 113.11, 114.64 (2C_{indole}), 117.78, 118.77, 121.59 (3CH_{indole}), 123.25 (C_{indole}), 124.27, 125.61, 129.62, 133.20 (4CH, 2C_{Ar}), 137.30 (CH_{indole}), 137.51, 142.33 (2 CN), 142.87, 146.21, 167.51 (3C_{kojic}), 173.66, 182.13 (2CO) ppm.

4g-II (RR/SS or RS/SR): yield 37 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.43-4.46$ (m, 2H, CH₂), 5.27 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.69 (d, 1H, ${}^{3}J_{\text{HH}} = 10.8 \text{ Hz}, \text{ CH}$), 5.79 (t, 1H, ${}^{3}J_{\text{HH}} = 6.4 \text{ Hz}, \text{ OH}$), 6.37 (s, 1H, CH_{koiic}), 7.20–7.30 (m, 2H, 2CH_{Ar}), 7.50–7.55 (m, 1H, CH_{Ar}), 7.64 (d, 2H, ${}^{3}J_{HH} = 8.4$ Hz, 2CH_{Ar}), 7.76 (d, 2H, ${}^{3}J_{HH} = 8.4$ Hz, 2CH_{Ar}), 8.04 (d, 1H, ${}^{3}J_{HH} = 8.0$ Hz, CH_{Ar}), 8.77 (s, 1H, CH–NH), 9.63 (s, 1H, OH), 12.44 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.44$, 44.25 (2CH), 59.86 (CH₂), 109.49 (CH_{kojic}), 111.57 (CH_{indole}), 113.12, 115.00 (2C_{indole}), 118.06, 118.99, 121.65 (3CH_{indole}), 123.29 (C_{indole}), 124.33, 125.70, 130.10, 133.34 (4CH, 2CAr), 137.37 (CH_{indole}), 137.52, 142.54 (2CN), 142.96, 146.90, 168.35 (3Ckoiic), 173.97, 182.92 (2CO) ppm; IR (KBr): $\overline{v} = 3,221$ (OH, NH), 2,231 (CN), 1,656, 1,626 (C=O), 1,585 (C=C), 1,042 (C-O) cm⁻¹; MS: m/z (%) = 439 (M⁺⁻, 3), 295 (M⁺⁻C₉H₆NO, 7), 144 $(M^+-C_{16}H_{11}N_2O_4, 100), 116 (M^+-C_{17}H_{11}N_2O_5, 21).$

3-(4-Bromophenyl)-3-[3-hydroxy-6-(hydroxymethyl)-4oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)propanenitrile (**4h**, C₂₄H₁₇Br N₂O₅) White powder, 0.45 g (93 %); m.p.: 223–225 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4h-I (RR/SS or RS/SR): yield 56 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.06$ and 4.25 (2d, AB system, 2H, ² $J_{\rm HH} = 15.2$ Hz, CH₂), 5.01 (d, 1H, ³ $J_{\rm HH} = 9.2$ Hz, CH), 5.78 (br s, 2H, 1CH, OH), 6.11 (s, 1H, CH_{kojic}), 7.21–7.69 (m, 7H, 7CH_{Ar}), 8.10 (d, 1H, ³ $J_{\rm HH} = 7.6$ Hz, CH_{Ar}), 8.89 (s, 1H, CH–NH), 9.38 (s, 1H, OH), 12.44 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.30$, 42.69 (2CH), 59.65 (CH₂), 109.31 (CH_{kojic}), 113.09 (CH_{indole}), 114.69, 117.92 (2C_{indole}), 121.65, 123.25, 124.30 (3CH_{indole}), 125.63 (C_{indole}), 130.78, 131.20, 132.15, 136.27 (4CH, 2C_{Ar}), 137.03 (CH_{indole}), 137.30 (CN), 142.25, 146.84, 167.39 (3C_{kojic}), 173.68, 182.39 (2CO) ppm.

4h-II (RR/SS or RS/SR): yield 37 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.38-4.53$ (m, 2H, CH₂),

5.18 (d, 1H, ${}^{3}J_{\text{HH}} = 10.8$ Hz, CH), 5.62 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.60–5.63 (m, 1H, OH), 6.37 (s, 1H, CH_{koiic}), 7.21–7.69 (m, 7H, 7CH_{Ar}), 8.06 (d, 1H, ${}^{3}J_{\rm HH} = 7.6$ Hz, CH_{Ar}), 8.77 (s, 1H, CH–NH), 9.39 (s, 1H, OH), 12.43 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 41.76, 43.81$ (2CH), 59.88 (CH₂), 109.42 (CH_{kojic}), 113.10 (CH_{indole}), 115.19, 118.23 (2C_{indole}), 121.96, 123.26, 124.31 (3CH_{indole}), 125.72 (C_{indole}), 130.79, 131.21, 132.28, 136.28 (4CH, 2C_{Ar}), 137.04 (CH_{indole}), 137.31 (CN), 142.56, 147.54, 168.26 (3C_{kojic}), 174.00, 183.22 (2CO) ppm; IR (KBr): $\overline{v} = 3,414$ (OH), 3,239 (NH), 2,258 (CN), 1,632 (C=O), 1,593 (C=C), 1,034 (C–O) cm⁻¹; MS: m/z (%) = 492 (M^{+,}, 1), 494 (M^{+,+}2, 1), 308 (M^+ -C₁₁H₇ N₂O, 15), 310 (M^+ +2-C₁₁H₇ N₂O, 19), 144 (M⁺-C₁₅H₁₁ BrNO₄, 100), 116 (M⁺-C₁₆H₁₁ BrNO₅, 23).

3-(2-Bromophenyl)-3-[3-hydroxy-6-(hydroxymethyl)-4oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)propanenitrile (**4i**, C₂₄H₁₇Br N₂O₅)

White powder, 0.44 g (90 %); m.p.: 219–221 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4i-I (RR/SS or RS/SR): yield 58 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.05$ and 4.25 (2dd, AB system, 2H, ² $J_{\rm HH} = 16.0$ Hz, ³ $J_{\rm HH} = 6.0$ Hz, CH₂), 5.63–5.77 (m, 3H, 2CH, OH), 6.12 (s, 1H, CH_{kojic}), 7.12–8.28 (m, 8H, 8CH_{Ar}), 8.86 (s, 1H, CH–NH), 9.29 (s, 1H, OH), 12.42 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 42.03$, 42.28 (2CH), 59.65 (CH₂), 109.23 (CH_{kojic}), 113.07 (CH_{indole}), 114.68, 117.66 (2C_{indole}), 121.68, 123.13, 124.22 (3CH_{indole}), 125.69 (C_{indole}), 128.42, 129.90, 130.48, 133.19, 133.55, 136.02 (4CH, 2C_{Ar}), 137.03 (CH_{indole}), 137.28 (CN), 142.78, 146.34, 167.52 (3C_{kojic}), 173.71, 182.29 (2CO) ppm.

4i-II (RR/SS or RS/SR): yield 32 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.35$ and 4.43 (2dd, AB system, 2H, ${}^{2}J_{\text{HH}} = 16.0 \text{ Hz}$, ${}^{3}J_{\text{HH}} = 6.0 \text{ Hz}$, CH₂), 5.63-5.77 (m, 3H, 2CH, OH), 6.36 (s, 1H, CH_{kojic}), 7.12-8.28 (m, 8H, 8CH_{Ar}), 8.73 (s, 1H, CH-NH), 9.43 (s, 1H, OH), 12.37 (s, 1H, NH) ppm; ¹³C NMR (100.6 MHz, DMSO- d_6): $\delta = 42.21, 42.85$ (2CH), 59.68 (CH₂), 109.24 (CH_{kojic}), 113.11 (CH_{indole}), 114.98, 117.86 (2C_{indole}), 121.84, 123.19, 124.28 (3CH_{indole}), 125.73 (C_{indole}), 128.74, 130.18, 130.76, 133.50, 133.65, 136.89 (4CH, 2CAr), 137.22 (CH_{indole}), 137.35 (CN), 143.14, 146.37, 168.40 (3Ckoiic), 174.08, 183.07 (2CO) ppm; IR (KBr): $\overline{v} = 3,426$ (OH), 3,242 (NH), 2,257 (CN), 1,655, 1,626 (C=O), 1,599 (C=C), 1,036 (C-O) cm^{-1} ; MS: m/z $(\%) = 492 (M^+, 4), 494 (M^{+}+2, 4), 347 (M^{+}-C_9H_6NO,$ 12), 349 (M^+ +2-C₉H₆NO, 14), 144 (M^+ -C₁₅H₁₁ BrNO₄, 100), 116 (M^+ - $C_{16}H_{11}$ BrNO₅, 10).

 $\label{eq:2.1} \begin{array}{l} 3-[3-Hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]-2-(1H-indol-3-ylcarbonyl)-3-(4-nitrophenyl)propanenitrile \\ \textbf{(4j, } C_{24}H_{17}\ N_3O_7\textbf{)} \end{array}$

White powder, 0.44 g (97 %); m.p.: 263–265 °C; $R_{\rm f} = 0.4$ (*n*-hexane/ethyl acetate 1:9 v/v).

4j-I (RR/SS or RS/SR): yield 57 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.06$ and 4.26 (2dd, 2H, ${}^{2}J_{\rm HH} = 16.0 \text{ Hz}, \; {}^{3}J_{\rm HH} = 6.0 \text{ Hz}, \; \text{CH}_{2}, \; 5.19 \; (d, \; 1\text{H},$ ${}^{3}J_{\text{HH}} = 11.6$ Hz, CH), 5.64 (t, 1H, ${}^{3}J_{\text{HH}} = 6.4$ Hz, OH), 5.87 (d, 1H, ${}^{3}J_{\text{HH}} = 11.6$ Hz, CH), 6.13 (s, 1H, CH_{koiic}), 7.26–7.31 (m, 2H, 2CH_{Ar}), 7.54 (d, 1H, ${}^{3}J_{HH} = 6.4$ Hz, CH_{Ar}), 7.93 (d, 2H, ${}^{3}J_{HH} = 8.8$ Hz, 2CH_{Ar}), 8.11 (d, 1H, ${}^{3}J_{\rm HH} = 7.2$ Hz, CH_{Ar}), 8.32 (d, 1H, ${}^{3}J_{\rm HH} = 8.8$ Hz, CH_{Ar}), 8.91 (d, 1H, ${}^{3}J_{HH} = 3.2$ Hz, CH–NH), 9.50 (s, 1H, OH), 12.46 (d, 1H, ${}^{3}J_{\text{HH}} = 3.2$ Hz, NH) ppm; ${}^{13}\text{C}$ NMR (100.6 MHz, DMSO- d_6): $\delta = 41.24$, 42.81 (2CH), 59.63 (CH₂), 109.36 (CH_{koiic}), 113.12 (CH_{indole}), 114.63, 117.73 (2C_{indole}), 121.59, 123.25, 124.37 (3CH_{indole}), 125.62 (C_{indole}), 129.96, 130.46, 137.20, 137.38 (4CH, 2CAr), 142.62 (CHindole), 144.26 (CN), 146.00, 147.49, 167.57 (3Ckoiic), 173.65, 182.03 (2CO) ppm.

4j-II (RR/SS or RS/SR): yield 40 %; ¹H NMR (400.13 MHz, DMSO- d_6): $\delta = 4.44-4.50$ (m, 2H, CH₂), 5.34 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.74 (d, 1H, ${}^{3}J_{\rm HH} = 10.8$ Hz, CH), 5.79 (t, 1H, ${}^{3}J_{\rm HH} = 6.8$ Hz, OH), 6.38 (s, 1H, CH_{koiic}), 7.26-7.31 (m, 2H, 2CH_{Ar}), 7.51 (d, 1H, ${}^{3}J_{HH} = 7.6$ Hz, CH_{Ar}), 7.74 (d, 2H, ${}^{3}J_{HH} = 8.8$ Hz, $2CH_{Ar}$), 8.04 (d, 1H, ${}^{3}J_{HH} = 7.2$ Hz, CH_{Ar}), 8.14 (d, 2H, ${}^{3}J_{\rm HH} = 8.8$ Hz, 2CH_{Ar}), 8.80 (d, 1H, ${}^{3}J_{\rm HH} = 3.2$, CH– NH), 9.67 (s, 1H, OH), 12.44 (d, 1H, ${}^{3}J_{HH} = 2.8$ Hz, NH) ppm; ¹³C NMR (100 MHz, CDCl₃): $\delta = 41.43$, 44.01 (2CH), 59.85 (CH₂), 109.48 (CH_{kojic}), 113.13 (CH_{indole}), 114.98, 118.03 (2C_{indole}), 121.65, 124.27, 124.49 (3CH_{in-} dole), 125.71 (Cindole), 129.97, 130.47, 137.31, 137.52 (4CH, 2C_{Ar}), 142.94 (CH_{indole}), 144.87 (CN), 146.69, 147.82, 168.42 (3Ckoiic), 173.96, 182.85 (2CO) ppm; IR (KBr): $\overline{v} = 3,222$ (NH, OH), 2,252 (CN), 1,656, 1,626 (C=O), 1,586 (C=C), 1,044 (C-O) cm⁻¹; MS: m/z (%) = 459 (M^{+.}, 1), 315 (M^{+.}-C₉H₆NO, 3), 144 $(M^+-C_{15}H_{11}N_2O_6, 100), 116 (M^+-C_{16}H_{11}N_2O_7, 21).$

General procedure for evaluation of antibacterial activity

Antibacterial activities of the synthesized 3-(cyanoacetyl)indole derivatives **4a–j** were assayed using Kirby– Bauer disc diffusion method, where a filter disc was impregnated with the compounds and placed on the surface of inoculated agar plates [49]. The synthesized compounds were dissolved into DMSO to achieve 20 mg cm⁻³ solution then filter sterilized using a 0.22-µm Ministart (Sartorius).

The antibacterial activities of the synthesized compounds were investigated against four bacterial species. Test organisms included E. coli PTCC 1330, P. aeruginosa PTCC 1074, S. aureus ATCC 35923, and B. subtilis PTCC 102 [50]. Late exponential phase of the bacteria was prepared by inoculating 1 % (v/v) of the cultures into the fresh Muller-Hinton broth (Merck) and incubating in an orbital shaker at 37 °C and 100 rpm overnight. Before using the cultures, they were standardized with a final cell density of approximately 10⁸ cfu cm⁻³. Muller–Hinton agar (Merck) was prepared and inoculated with the standardized cultures of the test organisms and then spread as uniformly as possible throughout the entire media. Sterile paper discs (6 mm diameter, Padtan, Iran) were impregnated with 20 mm^3 of the compound solution then allowed to dry. The impregnated disc was introduced on the upper layer of the seeded agar plate and incubated at 37 °C for 24 h. The antibacterial activities of the synthesized compounds were compared with known antibiotic gentamicin (10 µg/disc) and chloramphenicol (30 µg/disc) as positive control and DMSO (20 mm³/disc) as negative control. Antibacterial activity was evaluated by measuring the diameter of inhibition zone (mm) on the surface of plates, and the results were reported as mean \pm SD after three repeats.

Acknowledgments The authors acknowledge the University of Mazandaran for financial support of this research.

References

- 1. Tietze LF (1996) Chem Rev 96:115
- 2. Dömling A, Ugi I (2000) Angew Chem Int Ed 39:3169
- 3. Ramon DJ, Yus M (2005) Angew Chem Int Ed 44:1602
- 4. Dömling A (1998) Comb Chem High Throughput Screen 1:1
- 5. Wipf P, Kendall C (2002) Chem Eur J 8:1779
- Wangelin AJV, Neumann H, Gordes D, Klaus S, Strubing D, Beller M (2003) Chem Eur J 9:4286
- Bienayme H, Hulme C, Oddon G, Schmitt P (2000) Chem Eur J 6:3321
- Shiri M, Zolfigol MA, Kruger HG, Tanbakouchain Z (2010) Chem Rev 110:2250
- 9. Feng T, Li Y, Wang YY, Cai XH, Liu YP, Luo XD (2010) J Nat Prod 73:1075
- Houlihan WJ, Remers WA, Brown RK (1992) Indoles, part I. Wiley, New York
- 11. Sundberg RJ (1996) The chemistry of indoles. Academic Press, New York
- 12. Hashimoto Y, Shudo K, Okamoto T (1984) Chem Pharm Bull 32:4300
- Nakashima Y, Kawashima Y, Amanuma F, Sota K, Tanaka A, Kameyama T (1984) Chem Pharm Bull 32:4271

- 14. Cacchi S, Fabrici G (2005) Chem Rev 105:2873
- 15. Nair V, Vidya N, Abhilash KG (2006) Tetrahedron Lett 47:2871
- 16. Deb LM, Bhuyan JP (2007) Tetrahedron Lett 48:2159
- Bandini M, Melloni A, Umani Ronchi A (2004) Angew Chem Int Ed 47:2871
- 18. Gribble GW (2000) J Chem Soc Perkin Trans 1:1045
- 19. Xiong WN, Yang CG, Jiang B (2001) Bioorg Med Chem 9:1773
- 20. Jiang B, Yang CG, Wang J (2001) J Org Chem 66:4865
- 21. Sakagami M, Muratake H, Natsume M (1994) Chem Pharm Bull 42:1393
- 22. Fukuyama T, Chen X (1994) J Am Chem Soc 116:3125
- 23. Yadav DK, Patel R, Srivastava VP, Watal G, Yadav LDS (2010) Tetrahedron Lett 51:5701
- 24. Thirumurugan P, Perumal PT (2009) Tetrahedron Lett 50:4145
- Reddy BV, Reddy MR, Madan C, Kumar KP, Rao MS (2010) Bioorg Med Chem Lett 20:7507
- 26. Hong BC, Jiang Y, Chang Y, Lee S (2006) J Chin Chem Soc 53:647
- 27. Garcia LC, Martinez R (2002) Eur J Med Chem 37:261
- 28. Rossiter S, Folkes LK, Wardman P (2002) Bioorg Med Chem Lett 12:2523
- Queiroz MRP, Abreu AS, Carvalho MSD, Ferreira PMT, Nazareth N, Nascimento MS (2008) Bioorg Med Chem 16:5584
- 30. Zhu S, Ji S, Su X, Sun C, Liu Y (2008) Tetrahedron Lett 49:1777
- 31. Bauman N, Pease B, Hill C (1967) Fed Proc 26:507
- 32. Shen TY, Winter CA (1977) Adv Drug Res 12:89
- Radwan MAA, Ragab EA, Sabry NM, Shenawy SME (1997) Bioorg Med Chem 15:3832
- Abele E, Abele R, Dzenitis O, Lukevics E (2003) Chem Heterocycl Comp 39:3
- Franco LH, Joffe EBK, Puricelly L, Tatian M, Seldes AM, Palermo JA (1998) J Nat Prod 61:1130
- Novotny L, Rauko P, Abdel-Hamid M, Váchalková A (1999) Neoplasma 46:89
- Brtko J, Rondahl L, Fickova M, Hudecova D, Eybl V, Uher M (2004) Cent Eur J Publ Health 12:16
- Aytemir MD, Erol DD, Hider RC, Özal P (2003) Turk J Chem 27:757
- 39. Bentley R (2006) Nat Prod Rep 23:1046
- Uchino K, Nagawa M, Tanasaki Y, Oda M, Fukuchi A (1988) Agric Biol Chem 52:2609
- 41. Uher M, Konecny V, Rajniakova O (1994) Chem Pap Chem Zvesti 48:282
- Yamato M, Hashigaki K, Yasumoto Y, Sakai J, Luduena RF, Banerjee A (1987) J Med Chem 30:1897
- 43. Xiong X, Pirrung MC (2008) Org Lett 10:1151
- Fickova M, Pravdova E, Rondhai L, Uher M, Brtko J (2008) J Appl Toxicol 28:554
- Baharfar R, Baghbanian SM, Vahdat SM (2011) Tetrahedron Lett 52:6018
- 46. Baharfar R, Azimi R (2013) Synth Commun 44:89
- 47. Baharfar R, Shariati N (2013) C R Chim 17:413
- 48. Slätt J, Romero I, Bergman J (2004) Synthesis:2760
- Drago L, Mombelli B, Ciardo G, Vecchi ED (1999) J Chemother 11:207
- Ghaemy M, Aghakhani B, Taghavi M, Nasab SMA (2013) React Funct Polym 73:555